Patients diagnosed with either Huntington’s disease, spasticity or severe muscle spasms, or a terminal illness are now eligible to receive authorizations to access medical cannabis.
Members of the Ohio State Medical Board have approved requests to expand the list of qualifying conditions to include: arthritis, chronic migraines, and complex regional pain syndrome.
Some 30 percent of migraine patients have used cannabis to mitigate migraine pain. Among these users, 82 percent reported it to be effective at providing migraine relief.
More than two-thirds of chronic pain patients registered to legally access medical cannabis products substitute marijuana for prescription opioids, according to data published in The Journal of Headache and Pain Among those patients diagnosed specifically with headache/migraine, cannabis was frequently reported as a substitute for other medications – including opiates (43 percent), anti-depressants (39 percent), NSAIDS (21 percent), triptans (8 percent), and anti-convulsants (8 percent).
The prolonged daily administration of cannabinoids is associated with a reduction in migraine headache frequency, according to clinical trial data presented at the 3rd Congress of the European Academy of Neurology. “We were able to demonstrate that cannabinoids are an alternative to established treatments in migraine prevention,” researchers concluded.
Cannabis administration is associated with decreased migraine headache frequency, according to data published online ahead of print in the journal Pharmacotherapy. Authors reported that 85 percent of subjects reported a decrease in migraine frequency and 12 percent indicated that the use of cannabis prior to migraine onset would abort headaches.
As I wrote in the book Marijuana Is Safer: So Why Are We Driving People to Drink? (Chelsea Green, 2009), the word ‘intoxicant’ is derived from the Latin noun toxicum (poison).